<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569917</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0462</org_study_id>
    <nct_id>NCT03569917</nct_id>
  </id_info>
  <brief_title>Identification of Gut Microbiome Biomarkers Associated to Acquisition of Enterobacteriae Highly Resistant to Third Generation Cephalosporines Following Ceftriaxone Treatment.</brief_title>
  <acronym>ARCMI</acronym>
  <official_title>Identification of Gut Microbiome Biomarkers Associated to Acquisition of Enterobacteriae Highly Resistant to Third Generation Cephalosporines Following Ceftriaxone Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients receiving Ceftriaxone 1 gram or 2 grams per day during their presence in emergency
      unit of hospital whatever their medical condition, will be included.

      Rectal swabs will be collected at inclusion and at days 5 and 30 to perform analysis.

      Analysis will be performed to characterize gut microbiome in order to detect intestinal
      microbiome profiles significantly associated with protection against colonization by third
      generation cephalosporin resistant Enterobacteriae.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Anticipated">October 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of gut microbiome biomarkers</measure>
    <time_frame>30 days</time_frame>
    <description>The use of culture-independent techniques, metagenomics and metabolomics, will allow an exhaustive analysis of the intestinal microbiome in order to detect intestinal microbiome profiles (including species, modules, metabolites) significantly associated with protection against colonization by Enterobacteriae resistant to Cephalosporine. Acquisition of a risk index to Enterobacteriae resistance to third generation cephalosporin will be measured by the method developed by Montassier et al, 2016, Genome medicine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of gut microbiome biomarkers</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Patients Receiving Ceftriaxone in Hospital Emergency Unit</condition>
  <arm_group>
    <arm_group_label>patient under Ceftriaxone treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rectal swab collection</intervention_name>
    <description>Rectab swab collection will be performed at inclusion and 5 and 30 days later.</description>
    <arm_group_label>patient under Ceftriaxone treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years

          -  Able to comply with study requirement and to provide informed consent

          -  Outside the context of tutorship and / or guardianship, affiliated to the Social
             Security Regime and having consented to participate in the ARCMI study.

          -  Patient receiving ceftriaxone (1 gram or 2 grams per day) in the emergency department

        Exclusion Criteria:

          -  Patients with acute anorectal pathology incompatible with the swabbing strategy or
             digital rectal examination.

          -  Prescription of another dosage of ceftriaxone (more than 2 grams per day)

          -  Patient with inflammatory bowel disease

          -  Allergy or contraindication to betalactamines and cephalosporins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emmanuel MONTASSIER, Doctor</last_name>
    <phone>0240083333</phone>
    <email>emmanuel.montassier@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nantes university Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Reignier, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Jean Reignier, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes university Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MONTASSIER, Doctor</last_name>
      <phone>0240083333</phone>
      <email>emmanuel.montassier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanulel MONTASSIER, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

